Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)

José Estevez; Konrad Pesudovs

doi:10.1016/j.ophtha.2016.03.054

Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)

José Estevez, Konrad Pesudovs

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Abstract

To the Editor:

We read with interest the article by Pinto-Fraga et al.1 They examined a group of patients with moderate to severe dry eye disease (DED) treated with corticosteroids or polyvinyl alcohol for 3 weeks. The authors concluded that fluoromethalone 0.1% (FML, Allergan, Inc., Irvine, CA) topical eye drops maintained the ocular surface status of DED patients after an exposure to an “adverse environment.” Subjects treated with polyvinyl alcohol vehicle (Liquifilm Tears, Allergan) as the control were significantly impaired by the “adverse environment.” Additionally, the authors concluded that the 3-week course of topical FML 0.1% was safe for DED patients as there were no reported adverse events.

Original language	English
Pages (from-to)	e14
Number of pages	1
Journal	Ophthalmology
Volume	124
Issue number	2
DOIs	https://doi.org/10.1016/j.ophtha.2016.03.054
Publication status	Published - Feb 2017

Keywords

fluorometholone therapy
dry eye disease (DED)
Ocular surface inflammation
dessicating stress
Corneal staining

Access to Document

10.1016/j.ophtha.2016.03.054Licence: In Copyright

Cite this

@article{5a9790ec48db4eab950f1d48a54a931b,

title = "Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)",

abstract = "To the Editor:We read with interest the article by Pinto-Fraga et al.1 They examined a group of patients with moderate to severe dry eye disease (DED) treated with corticosteroids or polyvinyl alcohol for 3 weeks. The authors concluded that fluoromethalone 0.1% (FML, Allergan, Inc., Irvine, CA) topical eye drops maintained the ocular surface status of DED patients after an exposure to an “adverse environment.” Subjects treated with polyvinyl alcohol vehicle (Liquifilm Tears, Allergan) as the control were significantly impaired by the “adverse environment.” Additionally, the authors concluded that the 3-week course of topical FML 0.1% was safe for DED patients as there were no reported adverse events.",

keywords = "fluorometholone therapy, dry eye disease (DED), Ocular surface inflammation, dessicating stress, Corneal staining",

author = "Jos{\'e} Estevez and Konrad Pesudovs",

year = "2017",

month = feb,

doi = "10.1016/j.ophtha.2016.03.054",

language = "English",

volume = "124",

pages = "e14",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Re

T2 - Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)

AU - Estevez, José

AU - Pesudovs, Konrad

PY - 2017/2

Y1 - 2017/2

N2 - To the Editor:We read with interest the article by Pinto-Fraga et al.1 They examined a group of patients with moderate to severe dry eye disease (DED) treated with corticosteroids or polyvinyl alcohol for 3 weeks. The authors concluded that fluoromethalone 0.1% (FML, Allergan, Inc., Irvine, CA) topical eye drops maintained the ocular surface status of DED patients after an exposure to an “adverse environment.” Subjects treated with polyvinyl alcohol vehicle (Liquifilm Tears, Allergan) as the control were significantly impaired by the “adverse environment.” Additionally, the authors concluded that the 3-week course of topical FML 0.1% was safe for DED patients as there were no reported adverse events.

AB - To the Editor:We read with interest the article by Pinto-Fraga et al.1 They examined a group of patients with moderate to severe dry eye disease (DED) treated with corticosteroids or polyvinyl alcohol for 3 weeks. The authors concluded that fluoromethalone 0.1% (FML, Allergan, Inc., Irvine, CA) topical eye drops maintained the ocular surface status of DED patients after an exposure to an “adverse environment.” Subjects treated with polyvinyl alcohol vehicle (Liquifilm Tears, Allergan) as the control were significantly impaired by the “adverse environment.” Additionally, the authors concluded that the 3-week course of topical FML 0.1% was safe for DED patients as there were no reported adverse events.

KW - fluorometholone therapy

KW - dry eye disease (DED)

KW - Ocular surface inflammation

KW - dessicating stress

KW - Corneal staining

UR - http://www.scopus.com/inward/record.url?scp=85010188990&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2016.03.054

DO - 10.1016/j.ophtha.2016.03.054

M3 - Letter

C2 - 28126079

AN - SCOPUS:85010188990

SN - 0161-6420

VL - 124

SP - e14

JO - Ophthalmology

JF - Ophthalmology

IS - 2

ER -

Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this